IP Library › Granted Patent US 12,268,476
Granted Patent B2
US 12,268,476 · App. 17/268,209 · Granted Apr 8, 2025

Method and apparatus for managing acute ischemic events

Inventors: David Vale (Galway, IE); Brendan Casey (Galway, IE); Mahmood Mirza (Galway, IE); Ray McCarthy (Galway, IE); Patrick Connolly (Galway, IE)
Assignee: NEURAVI LIMITED
A61B5/02007A61B5/0035A61B5/0036A61B5/14546A61B5/7264A61B17/221A61B2017/00084A61B2017/22079A61B2017/2212A61B2017/2215A61B2217/005
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,268,476
App. No.
17/268,209
Granted
Apr 8, 2025
Kind
B2
Abstract

A method or use for managing one or more acute ischemic events. The method can include determining criteria of a clot; classifying the clot based on the criteria and generating a classification; determining an individualized treatment protocol for the clot based on the classification, the individualized treatment protocol comprising one or more techniques selected from using aspiration, restoring perfusion using a first reperfusion device, and/or restoring perfusion using a second reperfusion device; and treating the clot based on the individualized treatment protocol.

Claims (54)

1. A method or use for managing one or more acute ischemic events, the method or use comprising:

determining criteria of a clot;

classifying the clot based on the criteria and generating a classification;

determining an individualized treatment protocol for the clot based on the classification, the individualized treatment protocol comprising one or more techniques selected from using at least one of aspirating, restoring perfusion using a first reperfusion device, and restoring perfusion using a second reperfusion device; and

treating the clot based on the individualized treatment protocol,

wherein the first reperfusion device is a stent retriever configured to remove a clot or portions of a clot that are red blood cell rich and the second reperfusion device is a pinch retriever configured to remove a clot or portions of a clot that are fibrin-rich;

wherein the determining criteria of the clot further comprises interpreting information, by a computing device in operative communication with the clot, about the clot to determine in real-time levels of red blood cell content, white blood cell content, levels of fibrin, a clot size, a clot shape, and/or a clot location in the vasculature; and

wherein the method or use further comprises:

receiving, through a graphical user interface of the computing device, the individualized treatment protocol;

monitoring, by the computing device, perfusion of the vessel with the clot; and,

alerting, by the computing device, in response to perfusion being restored in the vessel.

2. The method or use according to claim 1 , wherein the determining criteria of the clot comprises:

delivering a catheter to a site of the clot in the vasculature;

taking a first reading of the clot by a using instrumentation for near infrared spectroscopy (NIR) coupled to the catheter at a first location of the site of the clot in the vasculature; and

generating a spectrum from the first reading, whereby the spectrum relates to at least one of a chemical composition and physical properties of the clot.

3. The method or use according to claim 2 , wherein the determining criteria of the clot further comprises: interpreting information contained in the spectrum to determine in real-time at least one of levels of red blood cell content, white blood cell content, levels of fibrin,

a clot size, a clot shape, and a clot location in the vasculature.

4. The method or use according to claim 2 , further comprising:

taking a second reading of the clot by using the instrumentation for NIR at a second location distal or proximal of the clot and the first location;

generating a spectrum from the second reading, whereby the spectrum of the second reading relates to at least one of a chemical composition and physical properties of the clot; and

interpreting information contained in the spectrum of the first reading and the second reading to determine in real-time at least one of levels of red blood cell content, levels of white blood cell content, levels of fibrin, a clot size, a clot shape, and a clot location in the vasculature.

5. The method or use according to claim 1 , wherein the classifying the clot is carried out in vivo.

6. The method or use according to claim 1 , wherein if the classification demonstrates that the clot is red blood cell rich, then the individualized treatment protocol comprises: passing the first reperfusion device by, through, or about the clot and then retracting the first perfusion device while engaging the clot in a lumen of the first reperfusion device to restore reperfusion to the vessel.

7. The method or use according to claim 1 , wherein if the classification demonstrates that the clot is fibrin-rich, then the individualized treatment protocol comprises passing the second reperfusion device by, through, or about the clot and then retracting the second perfusion device while pinching the clot to restore reperfusion to the vessel.

8. The method or use according to claim 1 , wherein the determining criteria of the clot further comprises interpreting information, by a computing device in operative communication with the clot, wherein the computing device is linked to a database comprising correlation data for interpreting information about the clot and determining the individualized treatment protocol;

wherein the database is remote from the computing device.

9. The method or use according to claim 1 , wherein the determining criteria of the clot comprises:

delivering a catheter to a site of the clot in the vasculature;

taking a first reading of the clot by a using instrumentation for Raman spectroscopy coupled to the catheter at the site of the clot in the vasculature; and

generating a spectrum from the first reading, whereby the spectrum relates to at least one of a chemical composition and physical properties of the clot.

10. The method or use according to claim 9 , wherein the determining criteria of the clot further comprises: interpreting information contained in the spectrum to determine in real-time at least one of levels of red blood cell content, white blood cell content, levels of fibrin, a clot size, a clot shape, and a clot location in the vasculature.

11. The method or use according to claim 9 , further comprising:

taking a second reading of the clot by using the instrumentation for Raman spectroscopy at a second location distal or proximal of the clot and the first location;

generating a spectrum from the second reading, whereby the spectrum of the second reading relates to a chemical composition and/or physical properties of the clot; and

interpreting information contained in the spectrum of the first reading and the second reading to determine in real-time at least one of levels of red blood cell content, white blood cell content, levels of fibrin, a clot size, a clot shape, and/or a clot location in the vasculature.

12. The method or use according to claim 1 , wherein the treating of the clot comprises retrieving a portion of the clot, the method or use further comprising: analyzing the retrieved clot and/or one or more fragments of the clot; and selecting a clot treatment step based on analyzing the retrieved clot or analyzing accessing and crossing the clot.

13. The method or use according to claim 1 , wherein the determining criteria of the clot comprises: determining one or more quantitative indications selected from one or more of white blood cell levels, red blood cell levels, serum levels, fibrin levels, clot size, clot location, clot strength, clot elasticity, rate of clot formation or rate of clot lysis.

14. The method or use according to claim 13 , further comprising: comparing a first and a second clot characteristic quantitative indications to correlation data and determining at least one of a selection and order of using one or more techniques selected from aspiration, the first reperfusion device, and/or the second reperfusion device.

15. A method or use for managing one or more acute ischemic events, the method or use comprising:

determining criteria of a clot;

classifying the clot based on the criteria and generating a classification;

determining an individualized treatment protocol for the clot based on the classification, the individualized treatment protocol comprising one or more techniques selected from using at least one of aspirating, restoring perfusion using a first reperfusion device, and restoring perfusion using a second reperfusion device; and

treating the clot based on the individualized treatment protocol,

wherein the first reperfusion device is a stent retriever configured to remove a clot or portions of a clot that are red blood cell rich and the second reperfusion device is a pinch retriever configured to remove a clot or portions of a clot that are fibrin-rich;

wherein the determining criteria of the clot further comprises interpreting information, by a computing device in operative communication with the clot, wherein the computing device is linked to a database comprising correlation data for interpreting information about the clot and determining the individualized treatment protocol;

wherein the database is remote from the computing device.

16. A method or use for managing one or more acute ischemic events, the method or use comprising:

determining criteria of a clot;

classifying the clot based on the criteria and generating a classification;

determining an individualized treatment protocol for the clot based on the classification, the individualized treatment protocol comprising one or more techniques selected from using at least one of aspirating, restoring perfusion using a first reperfusion device, and restoring perfusion using a second reperfusion device; and

treating the clot based on the individualized treatment protocol,

wherein the first reperfusion device is a stent retriever configured to remove a clot or portions of a clot that are red blood cell rich and the second reperfusion device is a pinch retriever configured to remove a clot or portions of a clot that are fibrin-rich;

wherein the determining criteria of the clot comprises: determining one or more quantitative indications selected from one or more of white blood cell levels, red blood cell levels, serum levels, fibrin levels, clot size, clot location, clot strength, clot elasticity, rate of clot formation or rate of clot lysis;

further comprising: comparing a first and a second clot characteristic quantitative indications to correlation data and determining at least one of a selection and order of using one or more techniques selected from aspiration, the first reperfusion device, and/or the second reperfusion device.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2021
From: VALE, DAVID; CASEY, BRENDAN; MIRZA, MAHMOOD; MCCARTHY, RAY; CONNOLLY, PATRICK
To: NEURAVI LIMITED
Reel/Frame 055244/0618 →
Continuity (6)
Provisional Application 62844559 · May 7, 2019
Provisional Application 62785566 · Dec 27, 2018
Provisional Application 62785543 · Dec 27, 2018
Provisional Application 62782217 · Dec 19, 2018
Provisional Application 62722648 · Aug 24, 2018
Related Publication 20210315599A1 · Oct 14, 2021
References Cited (27)
US 8777976B2 · Brady et al. · 2014 [cited by applicant]
US 8852205B2 · Brady et al. · 2014 [cited by applicant]
US 9402707B2 · Brady et al. · 2016 [cited by applicant]
US 9445829B2 · Brady et al. · 2016 [cited by applicant]
US 9642639B2 · Brady et al. · 2017 [cited by applicant]
US 10667833B2 · Vale et al. · 2020 [cited by applicant]
US 20080194993A1 · McLaren et al. · 2008 [cited by applicant]
US 20080300493A1 · Gatto · 2008 [cited by examiner]
US 20160029960A1 · Toth et al. · 2016 [cited by applicant]
US 20170055908A1 · Radman et al. · 2017 [cited by applicant]
US 20170071614A1 · Vale · 2017 [cited by examiner]
US 20170196577A1 · Sperry et al. · 2017 [cited by applicant]
US 20190000492A1 · Casey et al. · 2019 [cited by applicant]
US 20190374128A1 · Palushi et al. · 2019 [cited by applicant]
US 20200046267A1 · Govari · 2020 [cited by examiner]
EP 3335647A2 · 2018 [cited by applicant]
JP 2011507633A · 2011 [cited by applicant]
JP 201886267A · 2018 [cited by applicant]
WO 2015000953A1 · 2015 [cited by applicant]
WO 2015189354A1 · 2015 [cited by applicant]
WO 2017142874A2 · 2017 [cited by applicant]
WO 2018096182A2 · 2018 [cited by applicant]
International Search Report issued in corresponding International Patent Application No. PCT/IB2019/000942 dated Feb. 10, 2020. [cited by applicant]
Notification of Reasons for Refusal issued in Japanese Patent Application No. 2021-510018 dated Jun. 20, 2023, English translation only. [cited by applicant]
Translation of Chinese Office Action dated Apr. 28, 2024, issued in corresponding CN Application No. 201980070399.1. [cited by applicant]
Chinese Office Action dated Apr. 28, 2024, issued in corresponding CN Application No. 201980070399.1. [cited by applicant]
European Search Report dated Jan. 20, 2025, in corresponding EP 24209442.3, and submitted herewith. [cited by applicant]